InterMune discovers and advances small‑molecule inhibitors and monoclonal antibodies that block key profibrotic pathways such as TGF‑β and PDGF to treat idiopathic pulmonary fibrosis and other lung fibrotic diseases. The company integrates companion‑diagnostic biomarkers for patient stratification and employs adaptive Phase II/III trials to accelerate regulatory approval, generating revenue from product sales and licensing royalties.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with serious pulmonary and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) have few disease‑modifying treatment options, leading to high morbidity, mortality, and limited quality of life.
Solution
InterMune applies a targeted‑therapy approach to develop novel small‑molecule and biologic drug candidates that intervene directly in the molecular pathways driving lung fibrosis. The company conducts end‑to‑end drug development—from discovery and preclinical validation through adaptive clinical trials—to achieve regulatory approval for disease‑modifying therapies. By integrating companion‑diagnostic biomarkers, InterMune aims to identify patients most likely to benefit and to personalize dosing regimens. The pipeline is structured to address multiple fibrotic indications, providing a scalable platform for expanding therapeutic reach beyond IPF. Commercialization plans include direct product launch and strategic licensing partnerships to accelerate market access.
Target Audience
Primary customers are pulmonologists and interstitial lung disease specialists treating IPF and related fibrotic conditions, as well as pharmaceutical partners seeking licensed, disease‑modifying lung‑fibrosis therapeutics.
Features
- Small‑molecule inhibitors that block fibroblast activation and extracellular matrix deposition pathways (e.g., TGF‑β, PDGF signaling)
- Monoclonal antibodies targeting profibrotic cytokines and receptors to halt disease progression
- Oral and injectable formulations optimized for pulmonary delivery and systemic exposure
- Integrated biomarker program using circulating and imaging markers for patient stratification and response monitoring
- Robust preclinical models (human lung organoids, bleomycin‑induced fibrosis) supporting translational relevance
- Adaptive Phase II/III clinical trial designs with interim analyses to streamline development timelines
- Regulatory strategy aligned with FDA’s Fast Track and EMA’s PRIME pathways for accelerated review
- Partnership framework for co‑development, out‑licensing, and joint commercialization with pharma partners